Introduction
Preoperative (neoadjuvant) chemotherapy is a standard approach for the treatment of patients with breast cancer because it can shrink the tumor, so breast-conserving surgery can be performed. In addition, for a considerable proportion of patients with inoperable breast cancer, the disease becomes operable after neoadjuvant chemotherapy. In general, neoadjuvant chemotherapy achieves an overall response rate of 85-90%, including complete response (CR) in 15-20% of cases. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, 10-15% of patients have less than a partial response (PR), which leaves them with either stable disease or progressive disease. Many studies, including our own, have indicated that tumors that are refractory to neoadjuvant chemotherapy have higher metastatic rates than those that respond. Between 1974 and 1998 at The University of Texas M.D. Anderson Cancer Center, we treated 177 patients with breast cancer that was refractory to neoadjuvant chemotherapy and found that these patients had high rates of both locoregional and distant recurrence. For patients who did not have a good response to neoadjuvant chemotherapy, the estimated 10-year disease-free survival was only 25%. 9 For patients whose tumors remain inoperable after neoadjuvant chemotherapy, the optimal management strategy is less clear. Typically, both gross residual disease in the axilla or supraclavicular fossa that cannot be completely resected without excessive morbidity and significant residual disease in the breast that cannot be completely resected using primary skin closure have been considered inoperable. Our management approach in such cases has been to use preoperative radiation therapy (RT) in the hope that a modified radical mastectomy would become possible. Another promising approach is the use of non-cross resistant high-dose alkylating agents. In this study, our objectives were to assess the feasibility of using high-dose chemotherapy (HDCT) supported by autologous peripheral blood stem cell (PBSC) transplantation in patients with primary breast cancer that was refractory to neoadjuvant chemotherapy and to examine its long-term outcome in terms of overall survival (OS) and progressionfree survival (PFS).
Patients and methods

Patients and workup
Eligibility criteria included histological confirmation of invasive carcinoma of the breast without distant metastasis, less than PR to neoadjuvant chemotherapy for noninflammatory breast cancer (IBC) or less than CR for patients with IBC. The tumor response to neoadjuvant chemotherapy was determined by both physical examination and radiographic studies (mammography or breast sonography). The final tumor response was determined in a multidisciplinary conference that included breast surgical oncologists, breast medical oncologists, radiation oncologists, radiologist and bone marrow transplantation physicians. Patients with less than PR to either doxorubicin-or taxane-containing regimens were recommended to crossover to the other regimen before entering the study. Patients whose tumors remained inoperable after neoadjuvant chemotherapy were eligible regardless of the response. Other eligibility criteria included being age 60 years or less, having a Zubrod performance status of 0 or 1, and having adequate organ functions (serum creatinine o1.5 mg/dl; total bilirubin, SGOT and SGPT o3 Â normal; left ventricular ejection fraction X50%; and forced expiratory volume in 1 s and diffusing capacity of carbon monoxide X50% of predicted values). ). Mesna at 500 mg/m 2 was given i.v. 30 min before the first dose of cyclophosphamide, then as a continuous infusion of 2000 mg/m 2 over 24 h for 3 days (total dose: 6500 mg/m 2 ). 10 Filgrastim was administered subcutaneously (s.c.) at 6 mg/kg twice a day from day 4 until apheresis was completed. Peripheral blood stem cells were collected during hematopoietic recovery after a patient's white blood cell count recovered to 42 Â 10 9 /l. Apheresis was performed daily with a goal of collecting 4 Â 10 6 CD34 þ cells/kg. The minimum acceptable cell dose was 2 Â 10 6 CD34 þ cells/kg. The PBSCs were cryopreserved by programmed freezing in 5% dimethylsulfoxide before the preparative regimen was started. On the day of transplantation, the PBSCs were thawed and infused. 10 Filgrastim was administered s.c. daily from day 1 through the first day that the absolute neutrophil count reached 41000/mm 3 or for a maximum of 28 days.
Infection prophylaxis consisted of acyclovir and fluconazole plus oral quinolones or a nonabsorbable antibiotic during neutropenia. Irradiated blood products were administered to maintain a hemoglobin level of more than 8 g/dl and a platelet count of more than 20 Â 10 9 /l.
Post transplantation evaluation and response criteria Toxicity was assessed according to the National Cancer Institute Common Toxicity Criteria. Response to therapy was evaluated at 3, 6, 9 and 12 months and at other times as clinically indicated. Evaluation consisted of the patient's medical history, physical examination, blood counts, SMA-12 analysis, chest X-ray, bone scan, chest and abdominal/pelvic CT scans and tumor markers (CEA and CA 27-29). Mammography was performed once a year for patients with a preserved contralateral breast.
Complete remission was defined as the disappearance of all disease signs on physical and radiographic examinations for more than 1 month. PR was defined as a reduction of more than 50% in the sum of the products of the two greatest perpendicular diameters of each measurable lesion. Minor response (MR) was defined as a reduction of more than 25% but o50% in that sum. Stable disease was defined as anything between a 25% increase and a 50% reduction in that sum, and progressive disease was defined as the appearance of new lesions or more than a 25% increase in that sum.
Statistical considerations
Progression-free survival and OS were defined as the time from diagnosis to progression or death, respectively, using an intention-to-treat analysis. Progression-free survival and OS were estimated using the Kaplan-Meier product limited method, with time zero defined by the date of diagnosis. Treatment-related mortality was censored. The log-rank test was used to compare survival. A P-value of o0.05 was considered significant. All data were updated through August 12, 2004 .
Results
Patient characteristics
Forty-two female patients with primary breast cancer were registered to undergo HDCT supported with autologous PBSC transplantation between January 1997 and May 2002. The median age was 46 years (range 29-61 years). The patient characteristics are presented in Table 1 .
Patients were treated on this HDCT protocol after they had failed one (18 patients) or two (24 patients) neoadjuvant chemotherapy regimens. The median number of cycles was four (range, 1-6) for the first-line therapy and three (range, 1-11) for the second-line therapy. The details of the neoadjuvant chemotherapy regimens are presented in Table 2 . The median time from diagnosis to protocol registration was 8 months (range, 5-14 months).
After completion of neoadjuvant chemotherapy, six patients had progressive disease, and two of them remained inoperable. Twelve patients had MR, and three of them remained inoperable. Nineteen patients had stable disease, and five of them remained inoperable. Five patients had PR. Of those five, two with IBC had surgery, and the other three remained inoperable. Thus, a total of 13 patients remained inoperable.
Two patients had RT therapy before surgery. Twenty-nine patients had surgery before HDCT (25 patients had modified radical mastectomy, and four patients had segmental mastectomy). The median number of involved lymph nodes was six (range, 1-18). All eight patients with positive surgical margins received adjuvant chemotherapy. Thirteen patients were not operable and went directly to HDCT.
The median time between diagnosis and PBSC transplantation was 9 months (range, 6-16 months). The median time between the protocol registration and PBSC transplantation was 5 weeks (range, 5-9 weeks).
Toxicities
One patient did not receive a PBSC transplant because her disease progressed during the mobilization course. All other patients received the first dose of the mobilization regimen at a median of 7.8 months after diagnosis (range, 4.9-13.5 months). Thirty-four patients had toxic reaction of grade 3 or more during mobilization (see Table 3 ). Eighteen patients had neutropenic fever, and five of them also had additional grade 3 toxicities: nausea, hypotension, insomnia and diarrhea. Ten patients had documented infections; seven of them also had neutropenic fever. In two patients, two different microorganisms were found. Blood was the most common site where microorganisms were discovered (seven patients). Patients received autologous PBSCs after the conditioning regimen at a median of 8.9 months after diagnosis (range, 5.6-15.4 months). Median engraftment, determined by patients having an absolute neutrophil count higher than 5 Â 10 5 /l, was on day 8 (range, day 7-11). During the transplantation course, the total number of toxic reactions of grade 3 or higher was 43 (see Table 4 ). The most common toxicity was neutropenic fever, which affected 25 patients. Of those, 13 also had documented infections. The total number of patients with documented infection (all grades of toxicity) was 22, and in five patients more than one microorganism was found. Two patients had clinically diagnosed infections.
Pulmonary toxicity was second most common and reached grade 3 or higher in nine patients. Two patients (one patient in CR and one patient with progressive disease) had grade 5 (lethal) pulmonary toxicities. Carmustine was suspected to be the cause of pulmonary toxicity in one patient with a grade 5 toxic reaction and three patients with grade 3 reactions. In another five patients, grade 2 pulmonary toxicity suspected of being attributed to carmustine was recorded. Other toxicities of grade 3 or higher included edema, hematuria, anorexia, an increased bilirubin level and paresis. None of the patients developed secondary myelodysplastic syndrome or acute leukemia.
Outcome Treatment and outcome after HDCT are summarized in Table 5 . All 36 patients who did not receive RT before HDCT received it afterward; all 19 patients with hormone receptor-positive tumors received hormonal therapy.
In seven of the 13 patients (54%) whose disease was considered inoperable before HDCT, it became operable and they underwent modified radical mastectomy after HDCT. The best clinical responses in those seven patients were CR in two, PR in four and MR in one. The median number of involved lymph nodes was two (range, 0-11). In six patients (46%), the disease remained inoperable after HDCT. In two of those six, it became operable after subsequent RT. The best responses in those six patients were CR in one (a patient whose disease became operable after RT), PR in four (including the other patient whose disease became operable after RT), and progressive disease in one.
The best response after surgery, HDCT, and RT was assessed 60 days after transplantation. Thirty patients had CR, eight had PR, one had MR and three had progressive disease. Subsequently, disease progressed in 25 of the 42 patients (60%). Of those, eight patients had local progression (six in the chest wall, one in the contralateral breast and axilla, and one in a supraclavicular lymph node), 16 distant progression (in bone, lung, pleura, or liver, alone or in combination), and one had both local and distant progression (in the chest wall and liver).
The median time from diagnosis to progression was 19 months (range, 9-79 months). The median time from the start of neoadjuvant chemotherapy to progression was 18 months (range, 8-78 months). The median time from PBSC transplantation to progression was 9 months (range, 2-69 months). The patient who did not receive a PBSC transplant had progression 50 days after entering the protocol.
Twenty-one patients died. The median time from diagnosis to death was 24 months (range, 13-64 months). The median time from the start of neoadjuvant chemotherapy to death was 22 months (range, 11-61 months). The median time from PBSC transplantation to death was 13 months (range, 5-64 months). Nineteen patients died from disease progression, including a patient who did not receive a PBSC transplant. Two other patients died while in CR: one from autoimmune-mediated liver failure on day 151, and one from pulmonary failure on day 344.
After a median follow-up of 34 months (range, 5-87 months) from PBSC transplantation, or 42 months (range, 13-96 months) from the time of diagnosis, 21 patients were alive, and 15 of them remained disease free. Among the 29 patients who had surgery before HDCT, 14 patients remained without recurrence. Among the 13 patients whose disease was inoperable, three remained without recurrence. From the time of diagnosis, 3-year OS for the whole group was 57% (CI, 50-64%) (Figure 1 ) and 3-year PFS was Table 3 Mobilization course toxicity grade 3 or higher 45% (CI, 37-53%) (Figure 2 ). From the time of diagnosis, the estimated 5-year OS for the whole group was 52% (CI, 44-60%) and the estimated 5-year PFS was 40% (CI, 32-48%).
For patients with IBC, 3-year OS from the time of diagnosis was 56% (CI, 43-69%) (Figure 3) , and 5-year OS was 48% (CI, 34-62%); both 3-and 5-year PFS were 39% (CI, 25-53%) (Figure 4 ). For patients with non-IBC, 3-year OS was 57% (CI, 48-66%), and 5-year OS was 54% (CI, 45-63%) ( Figure 3) ; 3-year PFS was 49% (CI, 39-59%), and 5-year PFS was 41% (CI, 31-51%) (Figure 4) . The difference in OS and PFS was not statistically significant (P ¼ 0.5772 and 0.6748, respectively), but this result might be influenced by the small sample size.
There was a statistically significant difference in OS and PFS between patients whose disease was operable and inoperable after neoadjuvant chemotherapy. For patients with operable disease, 3-year OS was 72% (CI, 64-80%), and 5-year OS was 69% (CI, 60-78%) ( Figure 5) ; 3-year PFS was 57% (CI, 48-66%), and 5-year PFS was 50% (40-60%) (Figure 6 ). For patients with inoperable disease, 3-year OS was 23% (CI, 11-35%), and 5-year OS was 15% (CI, 5-25%) ( Figure 5) ; both 3-and 5-year PFS were 17% (CI, 6-28%) ( Figure 6 ). The differences in OS and PFS were statistically significant (P ¼ 0.0021 and 0.0189, respectively).
There was a statistically significant difference in OS and PFS between patients who had estrogen receptor-positive and -negative tumors. For patients, who had estrogen receptor-positive tumors, 3-year OS is 69% (CI, 50-70%) and 5-year OS is 64% (CI, 54-74%), 3-year PFS is 62% (CI, 51-63%), and 5-year PFS is 56% (45-67%). For patients, who had estrogen receptor-negative tumors, 3-year OS is 42% (CI, 31-53%), and 5-year OS were 37% (CI, 26-48%), 3-year PFS is 26% (CI, 16-36%), and 5-year PFS is 21% (12-30%). The differences in OS and PFS were statistically significant (P ¼ 0.0363 and 0.00259, respectively).
HER-2/neu status was known in only 22 patients. For patients, who had HER-2/neu-positive tumors, 3-year OS is 33% (CI, 14-52%) and 5-year OS is 17% (CI, 2-32%), 3-and 5-year PFS is 17% (CI, 2-32%). For patients, who had HER-2/neu-negative tumors, 3-and 5-year OS is 38% (CI, 26-50%), 3-year PFS is 41% (CI, 28-54%), and 5-year PFS is 31% (18-44%). The differences in OS and PFS did not reach statistical significance (P ¼ 0.7177 and 0.1988, respectively).
Discussion
Our findings show that HDCT with autologous PBSC transplantation is a feasible procedure as a part of a multidisciplinary approach for the treatment of primary breast cancer that is refractory to neoadjuvant chemotherapy.
To our knowledge, only one other study has examined extensively the characteristics of patients with breast cancer that is refractory to neoadjuvant chemotherapy. In a retrospective study of poor prognostic factors in patients whose breast cancer was refractory to anthracyclinecontaining neoadjuvant chemotherapy, our group found that these patients had heterogenous characteristic features that affected the overall outcome. Two factors shown to be markers of a poor prognosis were pathologic involvement of lymph nodes after standard-dose neoadjuvant chemotherapy and progressive disease during neoadjuvant chemotherapy. The actuarial OS rate at 5 and 10 years was 56 and 33%, respectively. The 5-and 10-year actuarial disease-free survival was 41 and 25%, respectively. 9 In our current study, 100% of patients had nodal involvement after standard-dose neoadjuvant chemotherapy (57% in more than four nodes), and 14% had progressive disease while recovering from the chemotherapy. In our earlier study, univariate analysis showed inoperable disease to be a significant prognostic factor, and 13 (31%) of the patients in the current study had inoperable disease.
What we did not know until now was the overall outcome for those who failed both anthracycline-and taxane-containing regimens. In the previous study, the patients did not receive a taxane-containing regimen in a neoadjuvant setting, and only 7% received it in an adjuvant setting. In the current study, 33 patients (78%) received a taxane-containing regimen. Despite failing both the anthracycline-and taxane-containing regimens, our patients had a 3-year PFS of 45% and a 3-year OS of 57%.
In this study, we confirmed that HDCT made inoperable breast cancer operable in 54% of the patients. However, in two (29%) of the seven patients whose disease became operable, the disease recurred rapidly in distant sites (liver and lung), and in two other patients, the disease recurred in the pleura. Our data confirm our earlier observation that patients whose disease remained inoperable after neoadjuvant therapy had a significantly worse outcome than patients whose disease became operable. 9 We did not see a difference in OS or PFS between patients whose disease became operable after HDCT and those whose disease remained inoperable (data not shown). This is most likely due to the small population of patients. It is important to note that a small fraction of patients may continue to survive without disease in this population with such a poor prognosis. The results seen in the patients in this study are very similar to those seen in patients who underwent autologous transplantation for metastatic breast cancer. 10, 11 However, given their high rate of relapse, this patient population can be a testing ground for novel therapy.
One important problem with this study is that the results could have been skewed due to selection bias. HDCT trials will always be subject to selection bias because of the strict criteria for transplantation and the extensive work-up done before a transplant to rule out occult metastatic disease. 12 Further, including patients with IBC in the study likely effected the overall outcome. Several studies have shown promising results from HDCT in patients with IBC. [12] [13] [14] [15] [16] To date, no randomized trial comparing HDCT and conventional therapy in IBC patients has been reported; however, PFS and OS were longer in these studies than in studies of the conventional multidisciplinary approach in IBC patients. In our study, patients with IBC had a 5-year OS of 48% and a 5-year PFS of 39%. When these data were compared to a historical control at our institution, the OS and PFS were better (Naoto Ueno, unpublished data). This observation suggests that HDCT may have a potential to be beneficial for patients with IBC.
Regimen-related toxicities and infections occurred at rates similar to those seen in other studies of autologous transplantation for breast cancer. No early treatmentrelated mortality was observed, although two patients had eventual toxicity-related deaths. All patients had durable engraftment. However, there appeared to be more possible carmustine-related pulmonary toxicities in this study group. These pulmonary toxicities may be partly due to the early application of RT after HDCT. 17, 18 In conclusion, autologous PBSC transplantation is a feasible procedure as a part of a multidisciplinary approach for patients with primary breast cancer that is refractory to neoadjuvant chemotherapy. The results are intriguing despite the poor prognosis for this group of patients; however, selection biases likely played some role in this. Randomized studies are needed to evaluate the role of HDCT suggested by these findings.
